PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA IEC | PubSys CalAccessCommittee header
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA IEC
Active cycles
2003-20042005-20062007-20082009-20102011-20122013-20142015-20162017-20182019-20202021-20222023-20242025-2026
Panel 2 • Finance overview
Committee finance snapshot
Scope: 2021-2022 cycle
- Raised
- $1,459,495Dated receipts + reported unitemized intervals
- Spent
- $1,936,051
- Net activity
- -$476,556
Receipt coverage evidence (37 components)
- Filing 2560971, amendment 0, F497P2: Receipt date 2021-02-25; $100,000.00; s497_not_received
- Filing 2583917, amendment 0, F497P1: Receipt date 2021-04-29; $50,000.00; covered_by_regular_filing
- Filing 2583917, amendment 0, F497P1: Receipt date 2021-04-29; $50,000.00; covered_by_regular_filing
- Filing 2583917, amendment 0, F497P1: Receipt date 2021-04-29; $1,899.00; covered_by_regular_filing
- Filing 2583917, amendment 0, F497P1: Receipt date 2021-04-29; $1,899.00; covered_by_regular_filing
- Filing 2583917, amendment 0, F497P2: Receipt date 2021-05-12; $75,000.00; s497_not_received
- Filing 2583917, amendment 0, F497P1: Receipt date 2021-04-29; $1,899.00; covered_by_regular_filing
- Filing 2665902, amendment 0, F497P2: Receipt date 2022-04-13; $125,000.00; s497_not_received
- Filing 2679341, amendment 0, F497P2: Receipt date 2022-05-03; $25,000.00; s497_not_received
- Filing 2683457, amendment 0, F497P2: Receipt date 2022-05-16; $8,650.31; s497_not_received
- Filing 2713557, amendment 0, F497P2: Receipt date 2022-08-23; $175,000.00; s497_not_received
- Filing 2716264, amendment 0, F497P2: Receipt date 2022-09-01; $75,000.00; s497_not_received
Panel 3 • Money structure snapshot
Money structure snapshot
$5,000+ is the largest bucket at 99.3% of dated attributable receipts.
Dominant category: Operations at 95.6% of spending.
Funding distribution
$5,000+
Count: 29
Share: 99.3%
Amount: $1,450,000
$1,000 - $4,999
Count: 5
Share: 0.7%
Amount: $9,495
Panel 5 • Financial evidence
Filings workspace
Filing history and transaction-level evidence moved to a dedicated page.
Open filings pageLarge-donor funded, Non-media-led spender, Active in 2021-2022 cycle.
Money over time
Dated receipts only; unitemized reporting intervals are not allocated to dates.
ContributionsExpenditures
Jan 2021Sep 2021Apr 2022Dec 2022
| $5,000+ | 29 | $1,450,000 | 99.3% |
| $1,000 - $4,999 | 5 | $9,495 | 0.7% |
Spending categories
Operations
Amount: $1,850,816
Share: 95.6%
Consulting
Amount: $85,235
Share: 4.4%
| Category | Amount | Share of spent |
|---|
| Operations | $1,850,816 | 95.6% |
| Consulting | $85,235 | 4.4% |
Panel 4 • Top donors
Top donors
| Donor | Total | Share* | Count | Last |
|---|
| ABBVIE | $100,000 | 6.9% | 2 | May 10, 2022 |
| AMGEN, INC. | $100,000 | 6.9% | 2 | Jul 18, 2022 |
| BAYER CORPORATION | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| BRISTOL-MYERS SQUIBB COMPANY | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| EISAI, INC. | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| ELI LILLY AND COMPANY | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| GENETECH, INC. | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| LUNDBECK INC. | $100,000 | 6.9% | 2 | May 10, 2022 |
| MERCK & CO. INC | $100,000 | 6.9% | 2 | Aug 4, 2022 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| SANOFI-AVENTIS | $100,000 | 6.9% | 2 | May 10, 2022 |
| TAKEDA PHARMACEUTICALS AMERICA INC. | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| UCB PHARMA, INC. | $100,000 | 6.9% | 2 | Mar 15, 2022 |
| ASTELLAS PHARMA US, INC. | $50,000 | 3.4% | 1 | Mar 15, 2022 |
| ASTELLAS PHARMA US, INC. | $50,000 | 3.4% | 1 | Mar 5, 2021 |
| GLAXOSMITHKLINE | $50,000 | 3.4% | 1 | May 10, 2022 |
| ALKERMES, INC. | $1,899 | 0.1% | 1 | Apr 29, 2021 |
| IPSEN BIOPHARMACEUTICALS, INC. | $1,899 | 0.1% | 1 | Apr 29, 2021 |
| JOHN VALENTI | $1,899 | 0.1% | 1 | Jul 18, 2022 |
| SAGE THERAPEUTICS | $1,899 | 0.1% | 1 | Mar 15, 2022 |
| SUNOVIAN, INC. | $1,899 | 0.1% | 1 | Apr 29, 2021 |
* Share is percent of committee total raised in the selected scope. Page rows are a subset and typically do not sum to 100%.